Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Agenix
Biotech company forecasts 5% decline in sales
July 6th, 2005
Biotechnology company Agenix (AGX; AGXLY) forecasts a lower full year loss for the year ended June 30, 2005, of between $12.3 million and $12.8 million, compared to a loss in the prior year of $14.3 million. This result includes costs of restructuring the business and is despite increased research and development expenditure resulting from the continuing success of ThromboView. Included in this loss is a $3 million pre-tax profit for the year from Agen Biomedical's human and animal health medical diagnostic businesses. Don Home, managing director of Agenix, commented: "The result is a mixture of continued success with our ThromboView program and...
Source: Biotech Week (2005-07-06)
|
